Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs

SAN FRANCISCO, Nov. 14, 2018 -- (Healthcare Sales & Marketing Network) -- Nektar Therapeutics (Nasdaq: NKTR) today announced the appointment of Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs. In this... Biopharmaceuticals, Oncology, Personnel Nektar Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news